National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Washington

International Aids Vaccine Initiative

University System of Maryland

Dana-farber-cancer Institute Inc.

Leland Stanford Junior University

University of Pennsylvania

Columbia University

Duke University

The Scripps Research Institute

Boston University

Other

Los Alamos National Security, LLC

Triad National Security, LLC

Sanofi

John R Mascola

Peter D Kwong

Tongqing Zhou

Gary J Nabel

Baoshan Zhang

Yongping Yang

Barney S Graham

Mark Connors

Ivelin Georgiev

Jeffrey C Boyington

Masaru Kanekiyo

Gwo-Yu Chuang

Xueling Wu

Zhi-yong Yang

Wing-Pui Kong

Michael Gordon Joyce

Cheng Cheng

Richard Wyatt

Hadi M Yassine

Aliaksandr Druz

Guillaume Stewart-Jones

Wei Shi

Young Do Kwon

Yaroslav Tsybovsky

Joseph G Sodroski

William Ray Schief

Marie Pancera

Ling Xu

Barton F Haynes

Antonio Lanzavecchia

Dennis R Burton

Davide Corti

Hua-Xin Liao

Beatrice H Hahn

Amos B Smith, Iii

Huawei Qiu

Bette T Korber

Sanjay K Phogat

Wayne C Koff

Ercole Rao

Christian Lange

George M Shaw

Pascal Raymond Georges Poignard

Feng Gao

Richard Schwartz

David Michael Jones

Jochen Kruip

Ernesto Freire

Christian Beil

Yuxing Li

Rebecca S Rudicell

Jiang Zhu

Lingshu Wang

Li Ou

Jinghe Huang

Mario Roederer

Gilad Ofek

Ulrich Baxa

Paul Thomas

Leo Laub

Carl-Magnus Hogerkorp

Jason Gorman

Kai Xu

Syed M Moin

Rebecca M Lynch

Man Chen

Cinque Soto

Joel R Courter

Zhi-Yong Yang

Jochen Beninga

Mallika Sastry

Joseph Van Galen

Barna Dey

Shi-Hua Xiang

Kizzmekia S Corbett

Wulf Dirk Leuschner

Wen Yuan

Thomas B Kepler

Scott D Boyd

Lawrence Shapiro

Rita Chen

Kayvon Modjarrad

Priyamvada Acharya

Emily Rundlet

Javier Guenaga

Julie Ledgerwood

Wayne A Hendrickson

Alexander W Sun

Amy M Princiotto

Judith M LaLonde

Navid Madani

Jonathan Cooper

Kevin Carlton

Michael Bender

Amarendra Pegu

Tatyana Gindin

Lisa Kueltzo

Theodore C Pierson

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises: i. an amino acid sequence that binds to a V1/V2 apex glycan epitope; ii. an amino acid sequence that binds to a V3-base glycan region epitope; iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope; iv. an amino acid sequence that binds to a gp120/gp41 interface epitope; and v. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope.

Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

Stabilized influenza hemagglutinin stem region trimers and uses thereof

Embodiments of immunogens based on the outer domain of HIV-1 gp120 and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to prime an immune response to gp120 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

Glycan-masked engineered outer domains of HIV-1 gp120 and their use

Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 Env fusion peptide immunogens and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

Neutralizing antibodies to HIV-1 GP41 and their use

Substitutions-modified prefusion RSV F proteins and their use

The present disclosure relates to multispecific antibodies targeting the human immunodeficiency virus-1 (HIV-1) envelope, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof in treatment and prevention of HIV infection.

Multispecific antibodies targeting human immunodeficiency virus and methods of using the same

Growing community of inventors

Rockville, MD, United States of America

John R Mascola